
Maria A Lagarkova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2200184/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ouabain-Induced Gene Expression Changes in Human iPSC-Derived Neuron Culture Expressing Dopamine and cAMP-Regulated Phosphoprotein 32 and GABA Receptors. Brain Sciences, 2021, 11, 203.	2.3	2
2	DNA G-Quadruplexes Contribute to CTCF Recruitment. International Journal of Molecular Sciences, 2021, 22, 7090.	4.1	15
3	Cerebral Organoids—Challenges to Establish a Brain Prototype. Cells, 2021, 10, 1790.	4.1	12
4	Chromosomal Translocations in NK-Cell Lymphomas Originate from Inter-Chromosomal Contacts of Active rDNA Clusters Possessing Hot Spots of DSBs. Cancers, 2021, 13, 3889.	3.7	6
5	New Insights into Therapy-Induced Progression of Cancer. International Journal of Molecular Sciences, 2020, 21, 7872.	4.1	14
6	Huntington's Disease—An Outlook on the Interplay of the HTT Protein, Microtubules and Actin Cytoskeletal Components. Cells, 2020, 9, 1514.	4.1	17
7	Methylation of the Human AR Locus Does Not Correlate with the Presence of Inactivated X Chromosome in Induced Pluripotent Stem Cells. Russian Journal of Genetics, 2020, 56, 339-344.	0.6	1
8	Transcription-facilitating histone chaperons interact with genomic and synthetic G4 structures. International Journal of Biological Macromolecules, 2020, 160, 1144-1157.	7.5	7
9	Spatial manipulation of magnetically-responsive nanoparticle engineered human neuronal progenitor cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102038.	3.3	15
10	"Necessity Is the Mother of Invention―or Inexpensive, Reliable, and Reproducible Protocol for Generating Organoids. Biochemistry (Moscow), 2019, 84, 321-328.	1.5	8
11	The Role of Mutant RNA in the Pathogenesis of Huntington's Disease and Other Polyglutamine Diseases. Molecular Biology, 2019, 53, 838-849.	1.3	7
12	Patient-Specific iPSC-Based Models of Huntington's Disease as a Tool to Study Store-Operated Calcium Entry Drug Targeting. Frontiers in Pharmacology, 2018, 9, 696.	3.5	21
13	Epigenetic reprogramming by naÃ ⁻ ve conditions establishes an irreversible state of partial X chromosome reactivation in female stem cells. Oncotarget, 2018, 9, 25136-25147.	1.8	5
14	Identification of mechanisms leading to blood-brain barrier dysfunction in Parkinson's disease. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-124.	0.0	0
15	Differentiation of Human Pluripotent Stem Cells into Mesodermal and Ectodermal Derivatives Is Independent of the Type of Isogenic Reprogrammed Somatic Cells. Acta Naturae, 2017, 9, 68-74.	1.7	1
16	Creation of a library of induced pluripotent stem cells from Parkinsonian patients. Npj Parkinson's Disease, 2016, 2, 16009.	5.3	74
17	Manifestation of Huntington's disease pathology in human induced pluripotent stem cell-derived neurons. Molecular Neurodegeneration, 2016, 11, 27.	10.8	140
18	An integrative analysis of reprogramming in human isogenic system identified a clone selection criterion. Cell Cycle, 2016, 15, 986-997.	2.6	32

#	Article	IF	CITATIONS
19	Genetic cell reprogramming: A new technology for basic research and applied usage. Russian Journal of Genetics, 2015, 51, 386-396.	0.6	8
20	Induction of pluripotency in human endothelial cells resets epigenetic profile on genome scale. Cell Cycle, 2010, 9, 937-946.	2.6	80
21	Efficient differentiation of hESCs into endothelial cells in vitro is secured by epigenetic changes. Cell Cycle, 2008, 7, 2929-2935.	2.6	38